Alisade (fluticasone furoate)
- Region
- 🇪🇺 EU
- Active substance
- fluticasone furoate
- Company
- Glaxo Group Ltd.
- Status
- Lapsed
- Therapeutic area
- Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal
- EU approval
- Mon 06 Oct 2008
- Application
- EMEA/H/C/001019
- ATC
- R01AD12
- Official record
- www.ema.europa.eu
Indication
Adults, adolescents (12 years and over) and children (6 - 11 years). Alisade is indicated for the treatment of the symptoms of allergic rhinitis.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Trelegy Ellipta Authorised · GlaxoSmithKline Trading Services Limited
- 🇪🇺 Elebrato Ellipta Authorised · GlaxoSmithKline Trading Services Limited
- 🇪🇺 Avamys Authorised · GlaxoSmithKline Trading Services Limited
- 🇪🇺 Revinty Ellipta Authorised · GlaxoSmithKline Trading Services Limited
- 🇪🇺 Relvar Ellipta Authorised · GlaxoSmithKline Trading Services Limited
- 🇪🇺 Temybric Ellipta Lapsed · GlaxoSmithKline Trading Services Limited
Follow Alisade
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.